Normally I would agree with you on this, meaning one CANNOT interpret the secondary endpoints if the primary endpoints have not been met. BUT, I think there will be an exception this time, because once this is put in front of the review panel, common sense will prevail. Meso's primary endpoint was set too low, as many have pointed out this is a SINGLE injection, and no medications can reduce mortality in any meaningful way. But MSB just achieved the hardest and most meaningful goal, to prolong lives.
Ann: Mesoblast Phase 3 Chronic Heart Failure Results, page-172
-
- There are more pages in this discussion • 851 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
-0.025(2.17%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.16 | $1.11 | $7.363M | 6.488M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 94863 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 5000 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |